BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16

• Press Releases

  WuXi Biologics’ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

  July 9, 2026

   · 

  4 min read
• Press Releases

  Alchemab Therapeutics Announces Largest Ever Life Sciences Investment From British Business Bank to Advance AI-Enabled Clinical Pipeline of Next Generation Human-Derived Antibodies

  July 9, 2026

   · 

  4 min read
• Press Releases

  InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

  July 9, 2026

   · 

  5 min read
• 

  Complete response letters

  FDA freezes CRL trove as ‘radical transparency’ push hits speedbump

  An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy “contravenes decades of agency practice.”

  July 9, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

  July 9, 2026

   · 

  8 min read
• Press Releases

  RYBODYN AWARDED $1.3M DOW GRANT TO ADVANCE NOVEL ANTIBODY THERAPIES FOR LUNG CANCER

  July 9, 2026

   · 

  5 min read
• Press Releases

  Study Reveals How Lung Tumors “Hack” into Nervous System to Starve the Body

  July 9, 2026

   · 

  7 min read
• Press Releases

  Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer

  July 9, 2026

   · 

  6 min read
• Press Releases

  Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers

  July 9, 2026

   · 

  4 min read
• 

  Neurodegenerative disease

  GSK abandons Alector after back-to-back neuro stumbles

  GSK and Alector first partnered in 2021 to advance two antibodies for neurodegenerative diseases. Both assets have since failed to show significant clinical benefit.

  July 9, 2026

   · 

  2 min read

   · 

  Tristan Manalac